Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419081 · ClinicalTrials.gov registry record · Phase 2
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00419081 is a Phase 2 study that was terminated before completion, run by BioCryst Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT00419081, a Phase 2 study, was terminated before completion, sponsored by BioCryst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
Interventions
- DRUG Forodesine Hydrochloride Sterile Solution, 5 mg/mL
- DRUG Forodesine Hydrochloride Capsules (100 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00419081
The ClinicalTrials.gov registry entry for NCT00419081 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Forodesine Hydrochloride Sterile Solution, 5 mg/mL is the first listed.
NCT00419081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00419081 about?
NCT00419081 is a clinical study titled "Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens". The purpose of this study is to determine whether Forodesine Hydrochloride is effective in treating patients with relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma who have failed two or more prior treatment regimens.
What is the current status of trial NCT00419081?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-07. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00419081?
The interventions under investigation include: Forodesine Hydrochloride Sterile Solution, 5 mg/mL (DRUG), Forodesine Hydrochloride Capsules (100 mg) (DRUG).
Who is sponsoring clinical trial NCT00419081?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.